FILING ANALYSIS · MONDAY, NOVEMBER 16
Invivyd, Inc. IVVD — 8-K: Results of Operations and Financial Condition
positive
Invivyd reported Q3 net product revenue growth of 18% and announced positive topline results from the LIBERTY Phase 3 clinical trial, demonstrating VYD2311 safety and tolerability superior to an mRNA-based COVID-19 vaccine. The company also announced the initiation of the FLINTLOCK Phase 2 clinical trial and investments in commercial preparedness for VYD2311.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →